Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EMBC 
Embecta Corp (EMBC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: EMBC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.67
1 Year Target Price $16.67
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 29.59% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 877.86M USD | Price to earnings Ratio 10.57 | 1Y Target Price 16.67 |
Price to earnings Ratio 10.57 | 1Y Target Price 16.67 | ||
Volume (30-day avg) 5 | Beta 1.08 | 52 Weeks Range 9.10 - 20.58 | Updated Date 09/14/2025 |
52 Weeks Range 9.10 - 20.58 | Updated Date 09/14/2025 | ||
Dividends yield (FY) 3.92% | Basic EPS (TTM) 1.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.58% | Operating Margin (TTM) 35.43% |
Management Effectiveness
Return on Assets (TTM) 3.8% | Return on Equity (TTM) - |
Valuation
Trailing PE 10.57 | Forward PE - | Enterprise Value 2148061636 | Price to Sales(TTM) 0.8 |
Enterprise Value 2148061636 | Price to Sales(TTM) 0.8 | ||
Enterprise Value to Revenue 1.95 | Enterprise Value to EBITDA 8.54 | Shares Outstanding 58485100 | Shares Floating 57239386 |
Shares Outstanding 58485100 | Shares Floating 57239386 | ||
Percent Insiders 0.47 | Percent Institutions 101.61 |
Upturn AI SWOT
Embecta Corp
Company Overview
History and Background
Embecta Corp. (EMBC) was spun off from Becton, Dickinson and Company (BDX) in April 2022. It focuses exclusively on diabetes care, specifically insulin delivery solutions.
Core Business Areas
- Diabetes Care: Develops, manufactures, and sells insulin pen needles and syringes for people with diabetes.
Leadership and Structure
Devdatt Kurdikar serves as the President and CEO. The company operates with a functional organizational structure focused on key areas like manufacturing, R&D, and commercial operations.
Top Products and Market Share
Key Offerings
- Insulin Pen Needles: Embecta is a leading manufacturer of insulin pen needles, used with insulin pens to deliver insulin. Market share is estimated to be approximately 25% globally. Competitors include Novo Nordisk (NVO), Owen Mumford, and HTL-Strefa. This is the largest revenue generating source for the company.
- Insulin Syringes: Embecta also manufactures insulin syringes for manual insulin injections. Market share is smaller than pen needles. Competitors include B. Braun Melsungen, and Terumo Corporation.
Market Dynamics
Industry Overview
The diabetes care market is driven by the increasing prevalence of diabetes globally. The insulin delivery market is competitive, with both established players and emerging technologies.
Positioning
Embecta is positioned as a pure-play diabetes care company focused on traditional insulin delivery methods, primarily pen needles and syringes. Their competitive advantage lies in their established brand, manufacturing scale, and global distribution network.
Total Addressable Market (TAM)
The TAM for insulin delivery devices is estimated to be over $10 billion. Embecta addresses a significant portion of this TAM through its established product portfolio, however new diabetes treatments are reducing the TAM.
Upturn SWOT Analysis
Strengths
- Established brand name
- Large-scale manufacturing capabilities
- Global distribution network
- Focus on diabetes care
- High product quality and safety
Weaknesses
- Limited product diversification (primarily pen needles and syringes)
- Dependence on traditional insulin delivery methods
- Vulnerability to market shifts towards alternative diabetes treatments
- High operating expenses compared to competitors
- Sales declining
Opportunities
- Expansion into adjacent diabetes care products
- Strategic partnerships with diabetes technology companies
- Geographic expansion in emerging markets
- Innovation in pen needle design and functionality
- Improved operational effeciency
Threats
- Increasing competition from alternative insulin delivery methods (e.g., insulin pumps, inhaled insulin)
- Pricing pressure from generic manufacturers
- Technological advancements in diabetes management (e.g., continuous glucose monitors, artificial pancreas)
- Changes in reimbursement policies
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- NVO
- TMO
Competitive Landscape
Embecta faces intense competition from larger, more diversified players. Its focus on traditional insulin delivery methods presents both an advantage (expertise) and a disadvantage (limited growth potential).
Major Acquisitions
Palni
- Year: 2023
- Acquisition Price (USD millions): 0
- Strategic Rationale: Acquired Palni, a product design and development company to develop a novel pen needle platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the recent spin-off and declining sales.
Future Projections: Analyst estimates project flat to slightly declining revenue growth in the near term.
Recent Initiatives: Focus on cost reduction and efficiency improvements. Exploring strategic partnerships.
Summary
Embecta is a diabetes care company specializing in insulin delivery devices. It faces market pressure from new treatments, leading to declining sales. It is working on cost reduction and product expansion. There is significant debt burden. Future results hinge on the success of new products and improved efficiency.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Analyst Reports
- Industry Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Financial data is based on publicly available information and may be subject to change. Investing in stocks involves risk, including the risk of loss.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Embecta Corp
Exchange NASDAQ | Headquaters Parsippany, NJ, United States | ||
IPO Launch date 2022-04-01 | President, CEO & Director Mr. Devdatt Kurdikar Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 2100 | Website https://www.embecta.com |
Full time employees 2100 | Website https://www.embecta.com | ||
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.